USPTO serial 79334430
U-LOAD
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 5, 2024
- Examiner
- ALLEN, BIANCA LEIGH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with U-LOAD?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Miriam D. Trudell
Miriam D. Trudell Davis Graham & Stubbs LLP3400 Walnut Street, Suite 700Denver, CO 80205United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry and science, in the nature of immune related chemicals for immune cell analysis, immune cell monitoring, immune cell detection and immune cell stimulation and immune related chemicals used in science in the nature of MHC monomer and multimer reagents, MR1 monomer and multimer reagents, CD1 monomer and multimer reagents, antibodies, antigen monomer and multimer reagents, reagents, diagnostic agents, control reagents, oligonucleotide conjugated multimer reagents in the nature of DNA/RNA oligo conjugated multimer reagents; diagnostic reagents for diagnostic being research use, other than medical and veterinary use, and scientific use; research diagnostic reagents for scientific use; diagnostic test materials for scientific and diagnostic, other than medical and veterinary, purposes, namely, diagnostic reagents and preparations, except for medical or veterinary use; diagnostic kits for scientific and diagnostic, other than medical and veterinary, purposes comprised of diagnostic reagents and preparations, except for medical or veterinary use and also comprised of immune related chemicals used in science, in the nature of MHC monomer and multimer reagents, MR1 monomer and multimer reagents, CD1 monomer and multimer reagents, antibodies, antigen monomer and multimer reagents, reagents, diagnostic agents, control reagents, oligonucleotide conjugated multimer reagents in the nature of DNA/RNA oligo conjugated multimer reagents; assays for research purposes; biochemical reagents for non-medical purposes, other than medical and veterinary; chemical and diagnostic preparations for analysis for research purposes related to vaccines and immunotherapy, cancer vaccines, borrelia vaccines, TB-vaccines, HIV-vaccines, CMV-vaccines and other vaccines, and for use in scientific research in connection with therapy and immunotherapy, in particular, for use in cancer therapy, cancer immunotherapy, for analysis of T-cell lymphoma, T-cell infiltration of solid tumors and tissue; chemical, and diagnostic preparations for analysis for research purposes related to analysis of infectious diseases, autoimmunity and for use in scientific research in connection with toxicological studies, transplantation, immune monitoring, and vaccines and T-cell monitoring; chemical reagents for other than medicinal and veterinary purposes | ACTIVE | — |
| 005 | Preparations for pharmaceutical purposes, namely, pharmaceutical preparations for the treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; preparations for medical purposes, namely, diagnostic preparations for medical purposes and medical preparations for treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; chemical-pharmaceutical preparations for treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; diagnostic preparations for medical purposes; vaccines; diagnostic preparations for analysis for medical purposes, hereunder for each of the abovementioned preparations for medical analysis of vaccines, immunotherapeutics and cellular therapies, in particular cancer vaccines and immunotherapeutics, borrelia vaccines, TB-vaccines, HIV-vaccines and CMV-vaccines, T-cell therapies, and for use in connection with cancer therapy or other therapy, for medical analysis and treatment of T-cell lymphoma, T-cell infiltration of solid tumors and tissue, and for infectious diseases; diagnostic preparations for analysis for medical purposes, hereunder for use in connection with toxicological studies, transplantation, immune monitoring, or vaccines and T-cell monitoring | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 13, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 13, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 13, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 6, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 5, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 5, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 19, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 19, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 18, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 29, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 29, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Nov 29, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 8, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 8, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 8, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 8, 2023 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Aug 14, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jul 26, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 26, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jul 20, 2023 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 20, 2023 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 20, 2023 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 21, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| May 3, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 27, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 27, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 2, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 14, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 27, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 27, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 2, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 1, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 24, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 1, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 25, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 24, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |